With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
Company to launch product after the expiry of semaglutide patent in India
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
